Drug or treatment

Ramucirumab clinical trials

• 11Clinical trials
• 11Countries

Newest trials

All recruiting trials (11)

• Zolbetuximab with paclitaxel and ramucirumab for CLDN18.2-positive stomach and gastro‑esophageal junction cancer

  This treatment tests whether adding zolbetuximab to paclitaxel and ramucirumab helps adults with metastatic gastro‑esophageal adenocarcinoma whose tumors are CLDN18.2‑positive live longer.

  Recruiting Phase 2 Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT06962137

• Nab‑paclitaxel PIPAC with paclitaxel and ramucirumab for stomach cancer that has spread to the peritoneum

  This phase I trial tests whether giving nab‑paclitaxel as a pressurized intraperitoneal aerosol (PIPAC) together with systemic paclitaxel and ramucirumab is safe and can help adults whose stomach cancer has spread to the peritoneal lining after first‑line therapy.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06675136

• Combining cemiplimab with standard treatment for advanced lung cancer

  This study is testing if adding the immunotherapy drug cemiplimab to standard treatments can help people with advanced lung cancer live longer and feel better compared to just the standard treatments alone.

  Recruiting at 399 sites Phase 2/3 SWOG Cancer Research Network · Daphne, Alabama and 412 other locations · NCT06616584

• Combining Nivolumab with Standard Treatment for Advanced Stomach or Esophageal Cancer

  This study is testing if adding nivolumab to the usual treatments for advanced stomach or esophageal cancer can help patients live longer and feel better.

  Recruiting at 338 sites Phase 2/3 National Cancer Institute (NCI) · Little Rock, Arkansas and 377 other locations · NCT06203600

• Combining zanidatamab with standard treatment for advanced HER2 positive gastroesophageal cancer

  This study is testing if adding a new drug called zanidatamab to standard treatments can help people with advanced HER2 positive gastroesophageal cancer live longer without their cancer getting worse.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 17 other locations · NCT06043427

• Combining TRK-950 with Ramucirumab and Paclitaxel for Gastric Cancer

  This study is testing if adding a new drug called TRK-950 to the standard treatments ramucirumab and paclitaxel can help people with gastric cancer live longer and feel better.

  Recruiting at 27 sites Phase 2 Toray Industries, Inc · Duarte, California and 26 other locations · NCT06038578

• Targeted treatment for advanced lung cancer with a specific gene change

  This study is testing if a new lung cancer treatment called tepotinib, with or without another drug called ramucirumab, can help people with advanced non-small cell lung cancer that has a specific gene change.

  Recruiting at 246 sites Phase 2 SWOG Cancer Research Network · Daphne, Alabama and 277 other locations · NCT06031688

• Combining Cyramza, ONIVYDE, and Lonsurf as a second-line treatment for metastatic gastric cancer

  This trial tests whether adding nal-IRI (ONIVYDE) and trifluridine/tipiracil (Lonsurf) to ramucirumab (Cyramza) helps people with metastatic gastric cancer who progressed after one prior systemic therapy.

  Recruiting Phase 1/2 National Health Research Institutes, Taiwan · Taipei, Taiwan/Taipei · NCT05927857

• Comparing targeted drug combinations for advanced lung cancer with specific gene changes

  This study is testing different combinations of targeted drugs to see if they can help people with advanced lung cancer that has specific gene changes live longer and feel better.

  Recruiting at 372 sites Phase 2 SWOG Cancer Research Network · Daphne, Alabama and 453 other locations · NCT05642572

• Testing ASP2138 for stomach and pancreatic cancer treatment

  This study is testing a new drug called ASP2138 to see if it can help adults with stomach or pancreatic cancer by boosting their immune response when used alone or with standard treatments.

  Recruiting at 42 sites Phase 1 Astellas Pharma Inc · Orange, California and 45 other locations · NCT05365581

• Combining ramucirumab with paclitaxel or FOLFIRI for advanced small bowel cancers

  This study is testing if combining a drug called ramucirumab with either paclitaxel or FOLFIRI can help people with advanced small bowel cancer live longer without their disease getting worse.

  Recruiting at 399 sites Phase 2 SWOG Cancer Research Network · Anchorage, Alaska and 535 other locations · NCT04205968

Quick answers

How many clinical trials of Ramucirumab are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in United States (8 trials), Japan (2 trials), South Korea (2 trials), Belgium (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 2/3: 2, Phase 1: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →